TriangleHEALTH PROFESSIONAL · SOURCE READING
Treatment options under clinical evaluation for bilateral intraocular retinoblastoma
Source: Retinoblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 3, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Intraocular Retinoblastoma / Treatment of Bilateral Intraocular Retinoblastoma
Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.
Source links and citations
The following is an example of a national and/or institutional clinical trial that is currently being conducted:
ARET2121 (NCT05504291) (A Study to Give Treatment Inside the Eye to Treat Retinoblastoma): This trial is exploring the feasibility of incorporating intravitreal melphalan injections during neoadjuvant systemic chemotherapy (carboplatin, vincristine, and etoposide). Patients are eligible if they have unilateral Group D retinoblastoma with vitreous seeding or bilateral retinoblastoma with the worst eye categorized as Group D and vitreous seeding.
Source links and citations
Studies cited in this source section
Source citation is not a determination that a study applies to you.
Preserved source evidence · Not medical advice